Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

Free Cash Flow · Q4 FY2024 · quarter ended Dec 2024

Free cash flow declines year over year

Q4 FY2024 free cash flow of $425.5 (cash outflow) fell 35.0% year over year. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -1.9% a year.

Context

  • Free cash flow grew in size in 1 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2024
-$425.5+0.0% QoQ
Last fiscal yearDec 2025
-$3.04M-16.1% YoY
LTMDec 2024
-$3.62K— YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.0%——
1 year-16.1%——
3-year CAGR-1.9%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(3.04M) USD
Year-over-year change
+16.1%

Free Cash Flow vs competitors

How MENS compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of -1.9% compares with a peer median of +23.9%.
MENS Competitors
Free Cash Flow for MENS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥1.2B CNY+785.9%+10.5%215.2%
DYNDyne Therapeutics, Inc.LTM Jun 2026$499.22M USD+37.9%+37.2%—
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$487.2M USD+18.0%-3.6%72.8%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$357.11M USD+41.0%+40.3%—
LEGNLegend Biotech CorporationLTM Sep 2026$320.88M USD+70.1%-9.1%23.6%
APGEApogee Therapeutics, Inc.LTM Jun 2026$243.95M USD+7.7%+141.9%—
CNTACentessa Pharmaceuticals plcLTM Mar 2026$209.17M USD+29.1%-1.3%—
CELCCelcuity Inc.LTM Jun 2026$192.16M USD+59.3%+61.9%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026$189.17M USD+61.5%+64.4%3068.0%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$134.22M USD+267.1%-54.4%20.6%
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024$3.62K USD—-1.9%—
Peer median (excluding MENS) —+50.2%+23.9%72.8%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Depreciation & Amortization122K123K127K120K100K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.24M2.94M1.12M(1.49M)20.74M
Accounts Receivables00000
Inventory00000
Accounts Payables21K(28K)(2K)1K(1K)
Other Working Capital1.22M2.97M1.12M(1.49M)20.74M
Other Non-Cash Items849K599K554K761K(19.21M)
Operating Cash Flow(1.98M)(2.97M)(2.6M)(3.62M)(3.04M)
Capital Expenditures(137K)(246K)000
Acquisitions (Net)00000
Purchases of Investments(1.83M)(292K)00(16.87M)
Sales of Investments664K1.93M95K016.87M
Other Investing Activities0000(13.51M)
Investing Cash Flow(1.31M)1.39M95K0(13.51M)
Debt Repayment(1.35M)3.61M2.47M2.2M(24K)
Common Stock Issued000017.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(35K)(276K)(445K)(213K)(114K)
Financing Cash Flow(1.38M)3.33M2.03M1.99M17.63M
Effect of Forex Changes67K(31K)(54K)(7K)(8K)
Net Change in Cash(4.61M)1.72M(532K)(1.64M)1.08M
Free Cash Flow(2.12M)(3.22M)(2.6M)(3.62M)(3.04M)

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.